The CD274 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the CD274 gene, which encodes the immune checkpoint ligand PD-L1, in the human pancreatic ductal adenocarcinoma cell line PaTu 8988t. This polyclonal population provides a heterogeneous loss-of-function model, generated through CRISPR/Cas9-mediated gene disruption, enabling the study of PD-L1-dependent immune evasion mechanisms without the clonal bias of a single-cell-derived line. The knockout product is optimized for applications requiring a population-level representation of CD274 deficiency, such as co-culture assays and high-throughput functional screens, where phenotypic variability reflects the spectrum of editing events across the cell pool.
The host cell line PaTu 8988t is a well-characterized epithelial cancer cell model derived from a liver metastasis of pancreatic adenocarcinoma, harboring oncogenic KRAS G12V and mutant TP53. These genetic lesions drive aggressive tumorigenic properties, including rapid proliferation, metastatic potential, and intrinsic immune evasion signaling. PaTu 8988t cells endogenously express PD-L1, particularly under stimuli like interferon-gamma (IFN-??), making them an ideal background to interrogate the contribution of CD274 to the immunosuppressive microenvironment characteristic of pancreatic ductal adenocarcinoma.
CD274 (PD-L1) functions as an immune checkpoint ligand that binds to the programmed death-1 (PD-1) receptor on T cells, delivering inhibitory signals that dampen T-cell receptor (TCR) activity. Mechanistically, PD-L1 engagement recruits the tyrosine phosphatase SHP-2, which dephosphorylates key signaling molecules including ZAP-70, LCK, and CD3??, thereby attenuating downstream pathways such as RAS/MAPK/ERK and PI3K/AKT/mTOR, and reducing the activity of transcription factors NFAT and NF-??B. In PaTu 8988t cells, CD274 expression is upregulated by oncogenic KRAS-driven MAPK signaling and by JAK/STAT pathway activation in response to IFN-??, with STAT1 and STAT3 acting as direct transcriptional regulators. Additional upstream modulators include MYC, HIF-1??, IL-6, and TNF-??, while PD-L1 also binds to B7-1 (CD80) to mediate additional immunoregulatory effects.
The disruption of CD274 in the PaTu 8988t background creates a powerful tool to dissect the role of the PD-1/PD-L1 axis in a KRAS-mutant pancreatic cancer context. Loss of PD-L1 expression can abrogate its interaction with PD-1 and CD80, relieving the suppression of TCR signaling and potentially restoring T-cell effector functions, including cytokine production and cytolytic activity. This model is particularly valuable for studying how oncogenic KRAS synergizes with IFN-?? signaling to maintain PD-L1 expression, and for assessing the impact of CD274 loss on tumor-intrinsic survival pathways such as mTOR/ERK signaling, which can be modulated by PD-L1 reverse signaling.
Research applications for this CD274 knockout polyclonal cell population span functional genomics, cancer immunology, and drug development. Typical assays include flow cytometry to confirm PD-L1 protein depletion, RT-qPCR and RNA-seq for transcript-level validation, and Western blotting for downstream signaling analysis (e.g., phospho-STAT1). The cells are ideally suited for co-culture experiments with activated T cells to evaluate tumor cell killing, cytokine release (e.g., IL-2, IFN-?? by ELISA), and the efficacy of anti-PD-L1 therapeutic antibodies. Additionally, the model supports combination therapy studies targeting parallel immune escape pathways and tumor microenvironment profiling. For further details, please contact Ascent Research.
